Moderna ( ($MRNA) ) just unveiled an update. On November 19, 2025, Moderna, Inc. entered into a Credit and Guaranty Agreement providing a $1.5 ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BeOne Medicines (ONC – Research Report), Moderna (MRNA – Research Report) and ...

CureVac ( ($CVAC) ) just unveiled an announcement. On November 25, 2025, CureVac N.V. announced the results of its Extraordinary General Meeting, ...

The post Market Analysis: Nov 27th, 2025 appeared first on Stock Target Advisor.

Despite posting a quarterly loss of €28.7 million, the management team demonstrated confidence by raising its full-year revenue guidance to a range of €2.6 to €2.8 billion. This signals a clear ...

C&EN networking event in New York City. Please join us if you’re in town! Here’s a link to the invitation. Questions? Comments? Tips? Let us know. Email Michael McCoy, C&EN’s executive editor for ...

CureVac N.V. recently reported its third quarter and nine-month earnings, revealing sales of €54.13 million and net income of €273.23 million for the quarter, both down substantially from the previous ...

Samyang Biopharm, a medical devices and biopharmaceutical affiliate of Samyang Group, soared on the Kospi on Monday as it ...

Market analysts are pointing to substantial growth potential for Pfizer Inc. following a challenging period for the ...

The investment community is watching with bated breath as BioNTech approaches a pivotal moment that could redefine its ...

Pharmaplan fully integrated into Exyte, unifying biopharma engineering capabilities under one European organization.

FDA's new vaccine strategy tightens approval rules after internal findings linked COVID-19 shots to several child deaths.